An Infant With Medulloepithelioma Successfully Treated by High-dose Chemotherapy Followed by Autologous Peripheral Blood Stem Cell Transplantation Without Radiotherapy.

Abstract

Medulloepithelioma of the central nervous system (CNS) is a rare primitive neuroectodermal tumor characterized by highly malignant behavior occurring in early childhood. Few cases have been reported and optimal management remains unknown. Here, we report a case of CNS medulloepithelioma successfully treated with high-dose chemotherapy (HDCTX) followed by autologous stem cell transplantation (auto-SCT) without radiotherapy. At the last follow-up, 3.0 years after onset, the patient was alive with no sign of relapse and normal development. To the best of our knowledge, this is the first reported case of long-term survival of CNS medulloepithelioma treated by HDCTX/auto-PBSCT without radiotherapy.

• Authors: Tomomi Hayase, Akira Morimoto, Yuta Kawahara, Masaki Yagi, Nobuyuki Kanai, Sumito Nobusawa, Junko Hirato, Akira Gomi
• Journal: Journal of pediatric hematology/oncology (J Pediatr Hematol Oncol) Vol. 37 Issue 6 Pg. e394-8 (Aug 2015) ISSN: 1536-3678 [Electronic] United States
• PMID: 26181425 (Publication Type: Case Reports, Journal Article)

Chemical References

• Busulfan
• Melphalan

Topics

• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Busulfan (administration & dosage)
• Child, Preschool
• Combined Modality Therapy
• Dose-Response Relationship, Drug
• Humans
• Induction Chemotherapy
• Male
• Melphalan (administration & dosage)
• Neuroectodermal Tumors, Primitive (pathology, therapy)
• Peripheral Blood Stem Cell Transplantation
• Prognosis
• Remission Induction
• Transplantation, Autologous